MUC16 and benign neoplasm: Combining HE‐4 with serum cancer antigen 125 (CA125) and the Risk of Malignancy Algorithm (ROMA) has become a power tool for diagnosing ovarian cancer and for distinguishing ovarian cancer from benign tumors.4